Roger Sun is a Managing Director of Matrix China. He joined Matrix China in 2016. Roger has led the investment in JYSS Bio-engineering, Naxions, Genecast, Grit Biotechnology, ClouDr Group, Taimei Technology, ExCell Biotech, Inscinstech, GLZHealth, etc.
Prior to Matrix China, Roger had 3 years of experience in healthcare investments, and before that, he worked in Deloitte Shanghai and interned at Roche and CFDA, respectively.
Roger graduated from Fudan University with a Bachelor of Pharmacy.